North America’s medical devices industry saw a rise of 9.52% in cross border deal activity in Q4 2020

Led by Koninklijke Philips’ $2.8bn acquisition of BioTelemetry, North America’s medical devices industry saw a rise of 9.52% in cross border deal activity during Q4 2020, when compared to the last four-quarter average, according to GlobalData’s deals database.

A total of 46 cross border deals worth $5.39bn were announced for the region during Q4 2020, against the last four-quarter average of 42 deals.

Of all the deal types, venture financing saw most activity in Q4 2020 with 26, representing a 56.5% share for the region.

In second place was M&A with 16 deals, followed by private equity deals with four transactions, respectively capturing a 34.8% and 8.7% share of the overall cross border deal activity for the quarter.

In terms of value of cross border deals, M&A was the leading category in the US medical devices industry with $3.71bn, while private equity and venture financing deals totalled $859.47m and $823.59m, respectively.

North America medical devices industry cross border deals in Q4 2020: Top deals

The top five medical devices cross border deals accounted for a 78.2% share of the overall value during Q4 2020.

The combined value of the top five cross border deals stood at $4.21bn, against the overall value of $5.39bn recorded for the quarter.

The top five medical devices industry cross border deals of Q4 2020 tracked by GlobalData were:

1) Koninklijke Philips’ $2.8bn acquisition of BioTelemetry

2) The $700m private equity deal with Verily Life Sciences by Alphabet, Ontario Teachers’ Pension Plan, Silver Lake Partners and Temasek Holdings (Private)

3) Richter Gedeon Nyrt’s $263.5m asset transaction with Janssen Pharmaceutica

4) The $250m acquisition deal with EmendoBio by AnGes

5) Baillie Gifford, Franklin Templeton Investments, Google, Novo Holdings and T Rowe Price Associates’ venture financing with Tempus Labs for $200m.

Verdict deals analysis methodology

This analysis considers only announced and completed cross border deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.